ClinicalTrials.gg
RecruitingNCT07204535TRUST-GBUpdated Jun 4, 2026

Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy

An observational study in Uterine Cervical Neoplasms, sponsored by Centre Paul Strauss. Recruiting at 2 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Centre Paul Strauss · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 147 studies in Uterine Cervical Neoplasms with a site in France — 31 open to participants now, 46 under way, 5 of them phase 3. Uterine Cervical Neoplasms · France.

Planned enrollment
23rd of 30
80 · median 174
Started
2025
with 8 others
Observational
30 of 147
9 open now
Primary completion
2030-11
later than 38 of 45 live
Registered
144th of 147
by date

Among the 147 studies in Uterine Cervical Neoplasms with a site in France, this one is the 23rd largest by planned enrollment of the 30 observational ones that give a count, is one of 9 that started in 2025, is one of 30 observational ones, reaches primary completion later than 38 of the 45 other live ones, and was the 144th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

31 of the 147 studies in Uterine Cervical Neoplasms with a site in France are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Uterine Cervical Neoplasms with a site in France, or all of them as a file.
02

Study summary

This is a multicenter, prospective study aimed at providing information on the psychological effects (including post-traumatic stress symptoms) of utero-vaginal brachytherapy in patients with cervical cancer using self-administered questionnaires. The study also aims to assess the persistence of these symptoms over time, up to 5 years after brachytherapy. The results could help identify patients at risk of post-traumatic stress in this context and develop appropriate psychological interventions to improve their psychological well-being during and after treatment.

03

Conditions studied

  • Uterine Cervical Neoplasms

Keywords

  • Brachytherapy
  • Post-TRaUmatic STress Disorder
  • Cervical cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with cervical cancer with an indication for High-dose rate (HDR) or pulse-dose rate (PDR) uterovaginal brachytherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of cervical cancer with an indication for High-dose rate (HDR) or pulse-dose rate (PDR) uterovaginal brachytherapy;
  • Squamous cell carcinoma or other histological types;
  • WHO ≤ 2;
  • Ability to complete validated questionnaires in French;
  • to participate in the study;
  • Patients over 18 years old

Exclusion criteria

Exclusion Criteria:

  • Inability to understand or respond to questionnaires due to a cognitive disorder, intellectual disability, language barrier, or psychiatric disorder that impairs judgment;
  • Patient under juridic protection;
  • Pregnant or breastfeeding woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
60 Months
Patient registry
Yes

Groups and cohorts

  • Patient with cervical cancer with an indication for uterovaginal brachytherapy

    Other: Prospective questionnaires

Interventions

  • OtherProspective questionnaires

    Post-traumatic stress disorder Checklist version DSM-5 (PCL-5) and quality of life questionnaires

06

What researchers measure

Primary outcomes

  1. Post-Traumatic Stress Disorder evaluation

    Evaluation with post-traumatic stress disorder Checklist version DSM-5 (PCL-5) - questionnaire with a Cut off score ≥ 32

    Time frame: at 2 months

Secondary outcomes

  1. Anxiety and Depression

    Hospital Anxiety and Depression scale

    Time frame: until 60 months

  2. Quality of Life (general module)

    Evaluated with EORTC QLQ-C30 questionnaire

    Time frame: until 60 months

  3. Quality of Life (cervical cancer module)

    Evaluated with EORTC QLQ-CX24 questionnaire

    Time frame: until 60 months

  4. Sexual Health evaluation

    Sexual Health Questionnaire (EORTC SHQ-22)

    Time frame: until 60 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2030, 60 months after the start.

Of 190 non-industry observational studies under Uterine Cervical Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 158. This study's planned 60 months is close to that.

Counting every sponsor, half of 214 studies reached it within 58 months; a quarter within 28 and three quarters within 158.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Nov 17, 2025
Primary completionEst.
Nov 17, 2030
CompletionEst.
Nov 17, 2031
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07204535
Lead sponsor
Centre Paul Strauss
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Nov 17, 2025
Primary completion
Nov 17, 2030 (estimated)
Completion
Nov 17, 2031 (estimated)
Last update
Jun 4, 2026

Study contacts

Valérie SARTORI
Contact
promotion-rc@icans.eu
368767223 ext. 33
Claire VIT
Contact
c.vit@icans.eu
388258529 ext. 33
George NOEL, MD, PhD
principal investigator · ICANS, CPS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion